MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - August 27, 2012) -
MorphoSys AG /
MorphoSys to Present at Three Upcoming Investor Conferences. Processed and
transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX)
will
present at three upcoming international investor conferences:
Commerzbank Sector Conference Week 2012
Date: August 28, 2012, 3:45pm CEST (9:45 am EDT, 2:45 pm BST)
Venue: Frankfurt, Germany
Participants: Dr. Simon Moroney, CEO of MorphoSys AG
Dr. Claudia Gutjahr-Loser, Head of Corporate
Communications & IR
Deutsche Boerse CEO Conference
Date: September 12, 2012, 3:00 pm CEST (9:00 am EDT, 2:00 pm BST)
Venue: Zurich, Switzerland
Participants: Jens Holstein, CFO of MorphoSys AG
Dr. Claudia Gutjahr-Loser, Head of Corporate
Communications & IR
Berenberg Bank and Goldman Sachs Inaugural German Corporate Conference
Date: September 24, 2012, 4:15 pm CEST (10:15 am EDT, 3:15 pm BST)
Venue: Munich, Germany
Participants: Dr. Simon Moroney, CEO of MorphoSys AG
Dr. Claudia Gutjahr-Loser, Head of Corporate
Communications & IR
The PDF version of the presentation will be provided at www.morphosys.com.
Links
to the webcast, if available, are filed under
www.morphosys.com/conference-calls.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology
in
the pharmaceutical industry. By successfully applying this and other
patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
The
Company's AbD Serotec unit uses HuCAL and other technologies to generate
superior monoclonal antibodies for research and diagnostic applications.
Through its own development efforts and successful partnerships in the
pharmaceutical industry, MorphoSys has built a therapeutic pipeline of more
than
70 human antibody drug candidates for the treatment of cancer, rheumatoid
arthritis, and Alzheimer's disease, to name just a few. With its ongoing
commitment to new antibody technology and drug development, MorphoSys is
focused
on engineering the medicines of tomorrow. MorphoSys is listed on the
Frankfurt
Stock Exchange under the symbol MOR. For regular updates about MorphoSys,
visit
http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®,
arYla®, Ylanthia®; and 100 billion high potentials® are registered
trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary
of MorphoSys AG.
This communication contains certain forward-looking statements
concerning the
MorphoSys group of companies. The forward-looking statements contained
herein
represent the judgment of MorphoSys as of the date of this release and
involve
risks and uncertainties. Should actual conditions differ from the
Company's
assumptions, actual results and actions may differ from those
anticipated.
MorphoSys does not intend to update any of these forward-looking
statements as
far as the wording of the relevant press release is concerned.
Conference Announcement:
http://hugin.info/130295/R/1636466/525877.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1636466]
